+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

The Antiangiogenic Therapy in Ovarian Cancer

Volume 4 - Issue 5

Loizzi Vera*1, Cicinelli Ettore1, Del Vecchio Vittoria1, Naglieri Emanuele2, Girolamo Ranieri3 and Gennaro Cormio 1,2

  • Author Information Open or Close
    • 1Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
    • 2Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
    • 2Interventional and Medical Oncology Unit, IRCCS Istituto, Tumori Giovanni Paolo II, Bari, Italy

    *Corresponding author: Vera Loizzi, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy, Piazza Giulio Cesare 11, Italy

Received: May 21, 2018;   Published: May 29, 2018

DOI: 10.26717/BJSTR.2018.04.001121

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The standard treatment for epithelial ovarian cancer (EOC) consists of optimal cytoreductive surgery followed by platinum-based chemotherapy [1-2]. Bevacizumab has been approved for the treatment of several tumors such as colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, epithelial ovarian, fallopian tube, and primary peritoneal cancers. The use of antiangiogenic agent in EOC is based on the results of randomized clinical trials which revealed an improved survival rates with the addition of bevacizumab to standard first-line chemotherapeutic drugs [3- 4].

Keywords: Angiogenesis, Vegf, Ovarian Cancer

Mini Review| References|